Forman Stephen J. 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Aug 3, 2022
Insider Transaction Report
Form 4
Forman Stephen J.
Director
Transactions
- Award
Options to Purchase Common Stock
2022-06-30+100,000→ 100,000 totalExercise: $0.74From: 2022-06-30Exp: 2027-06-30→ Common (100,000 underlying)
Holdings
- 50,000
Options to Purchase Common Stock
Exercise: $3.21From: 2021-01-06Exp: 2026-01-06→ Common (50,000 underlying) - 21,053(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $5.70From: 2018-12-07Exp: 2022-12-07→ Common (21,053 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common (8,333 underlying) - 16,667(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $6.00From: 2018-12-07Exp: 2022-12-07→ Common (16,667 underlying) - 100,000
Options to Purchase Common Stock
Exercise: $3.03From: 2021-06-30Exp: 2026-06-30→ Common (100,000 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $0.90From: 2017-10-16Exp: 2022-10-16→ Common (8,333 underlying)
Footnotes (1)
- [F1]Effective June 30, 2022, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2022).